Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Company News for Aug 4, 2022
12:31pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Companies in The News Are: MRNA, REGN, HZNP, EXC
Regeneron Shares Climb on Drug Sales, NASH Research
04:38pm, Wednesday, 03'rd Aug 2022
Regeneron Pharmaceuticals Inc. ( REGN , Financial) didn't just get past hump day, the company soared over it. Shares of the Tarrytown, New York-based drug company traded as high as $623 Wednesday befo
Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent
02:53pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.
U.S. Stock Futures Rise on Strong Q2 Earnings
02:24pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Stock futures have risen in today???s pre-market after two consecutive days of loss making.
Regeneron Pharmaceuticals, Inc.'s (REGN) CEO Leonard Schleifer on Q2 2022 Results - Earnings Call Transcript
02:07pm, Wednesday, 03'rd Aug 2022
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - Presi
Pre-markets Green on Strong Earnings Numbers
01:44pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Pre-markets Green on Strong Earnings Numbers.
Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent
12:02pm, Wednesday, 03'rd Aug 2022
Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.
Regeneron (REGN) Q2 Earnings and Revenues Beat Estimates
11:55am, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Regeneron (REGN) delivered earnings and revenue surprises of 14.54% and 3.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron Pharmaceutical Beats Second-Quarter Views But Logs No Covid Sales
09:03am, Wednesday, 03'rd Aug 2022
Regeneron Pharmaceutical beat second-quarter estimates on Wednesday, leaning on Eylea as its Covid drug logged no sales. REGN stock rose.
Regeneron (REGN) Q2 Earnings and Revenues Beat Estimates
09:02am, Wednesday, 03'rd Aug 2022
Regeneron (REGN) delivered earnings and revenue surprises of 14.54% and 3.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron quarterly profit slumps as COVID antibody sales dry up
06:39am, Wednesday, 03'rd Aug 2022
(Reuters) -Regeneron Pharmaceuticals reported a 72.5% fall in quarterly profit on Wednesday, hurt by lacklustre sales of its COVID-19 antibody cocktail after the U.S. health regulator decided to limit
July’s Big Rally Could Continue, But Consider The Risks
09:16am, Monday, 01'st Aug 2022 Investing.com
2 Cheap Dividend Stocks Yielding More Than 4%
11:45am, Sunday, 31'st Jul 2022 The Motley Fool
These two companies haven't performed well in the market recently, but that could be an opportunity for investors.
How This Multibillion-Dollar Company Is Shaking Off the Competition
02:45pm, Saturday, 30'th Jul 2022 The Motley Fool
The company has posted growth despite lower demand for several key products.
How This Multibillion-Dollar Company Is Shaking Off the Competition
10:45am, Saturday, 30'th Jul 2022
The company has posted growth despite lower demand for several key products.
